Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Monday

Rani Therapeutics (NASDAQ:RANI) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect Rani Therapeutics to post earnings of ($0.22) per share for the quarter.

Rani Therapeutics (NASDAQ:RANI) last issued its earnings results on Monday, March 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $1.03 million during the quarter. On average, analysts expect Rani Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rani Therapeutics Trading Up 0.9 %

RANI stock opened at $1.08 on Friday. Rani Therapeutics has a 1-year low of $1.02 and a 1-year high of $7.88. The business has a 50 day simple moving average of $1.31 and a two-hundred day simple moving average of $1.64. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60. The company has a market capitalization of $62.08 million, a price-to-earnings ratio of -1.02 and a beta of 0.24.

Analysts Set New Price Targets

Several research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Rani Therapeutics in a report on Thursday, April 3rd. Canaccord Genuity Group reiterated a “buy” rating and set a $9.00 price objective on shares of Rani Therapeutics in a research report on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $12.33.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.